Just - Evotec Biologics
United States
37 articles about Just - Evotec Biologics
-
Evotec SE: Invitation to Conference Call - Jan 22, 2024
1/22/2024
Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.
-
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
8/29/2023
Evotec SE announced its financial results and corporate updates for the first half-year of 2023.
-
Evotec Provides Update on Financial Impact of Cyber-Attack
7/27/2023
Evotec SE announces that it is adjusting its guidance for the fiscal year 2023.
-
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
7/11/2023
Evotec SE announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement.
-
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
7/5/2023
Evotec SE announced that the U.S. Department of Defense has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody -based drug product prototypes targeting orthopoxviruses.
-
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
6/29/2023
Evotec SE announced that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases.
-
Evotec Presents Sustainability Strategy
6/5/2023
Evotec SE presents an update on the Company's sustainability strategy and shares details on its ESG performance towards strengthening its competitiveness and contributing to a better future for next generations to investors and interested stakeholders at its virtual Capital Markets Day.
-
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
6/2/2023
Evotec SE announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing.
-
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
5/9/2023
Evotec SE and Sandoz AG, a division of Novartis announced that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.
-
Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer
5/3/2023
Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development Officer.
-
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
4/24/2023
Sernova Corp. announced the presentation of preclinical data supporting the anticipated 2024 IND submission and planned Phase 1/2 clinical trial of Evotec SE’s iPSC-derived ILCs in combination with Sernova’s implantable Cell Pouch device for the treatment of patients with T1D.
-
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
-
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
3/28/2023
Evotec SE reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.
-
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
3/28/2023
Evotec SE announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016.
-
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
3/24/2023
Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis.
-
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
3/16/2023
Evotec SE announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
-
Evotec Receives € 150 m Loan from European Investment Bank
2/10/2023
Evotec SE and the European Investment Bank announced that the EIB has granted Evotec an unsecured loan facility of € 150 m to support the Company's R&D activities, equity investments and the building of the new J.POD ® biologics manufacturing facility on Evotec's Campus Curie in Toulouse, France.
-
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
2/9/2023
Evotec SE announced that the Company has extended and expanded its integrated multi-target drug discovery agreement with data-driven biotech creation firm, Related Sciences, to continue to grow their joint portfolio of drug development candidates through 2030, leveraging Evotec's industry-leading capabilities across the full R&D continuum.
-
Evotec Completes Acquisition of Central Glass Germany
11/3/2022
Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
-
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
11/2/2022
Evotec SE presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access.